CGHS maps domestic manufacturing capacity for 153 critical drugs to shorten supply delays
In order to speed up drug procurement, CGHS has directed pharmaceutical manufacturers and authorized importers to submit regulatory and production filings for oncology, diabetes, spinal muscular atrophy therapy and bispecific antibody drugs.
The health ministry of India is mapping the domestic manufacturing capacity of 153 specialized medicines to improve the availability of critical drugs for beneficiaries of the Central Government Health Scheme (CGHS), according to two government officials and a reviewed document. This initiative aims to shorten supply delays and ensure a steady supply of essential medicines to those who need them.
Priyanka Sharma, a journalist at Mint, has provided insight into this development, highlighting the government's efforts to boost domestic manufacturing and streamline the distribution of important drugs.
Brief written by urgent.news from Live Mint's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
